ArticleBiomarker insights2025
The Additional Prognostic Value of Serial Biomarker Measurements for Extubation Failure Among Patients With COVID-19 Acute Respiratory Distress Syndrome.
Article in Biomarker insights, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Extubation failure is associated with adverse outcomes in critically ill patients. While single biomarker measurements can aid prediction, repeated biomarker measurements can help to timely recognize underlying diseases. Objectives: The aim of this study was to investigate the temporal evolution of cardiac (N-terminal pro-B-type natriuretic peptide [NT-proBNP], high-sensitivity troponin T [Hs-TnT]) and inflammatory biomarkers (interleukin-6 [IL-6] and procalcitonin [PCT]) prior to extubation and determine their additional prognostic value. Design: Retrospective cohort study. Methods: Patients with COVID-19 extubated after mechanical ventilation were included. Daily biomarker levels were collected up to 3 days before extubation. The primary endpoint was extubation failure, defined as reintubation or death within 7 days. Linear mixed-effect models were used to analyze biomarker trajectories in patients with extubation success and failure. Each day before extubation a logistic regression model (consisting of the 4 biomarkers) was constructed to determine the model with the best discriminative ability. Results: Among 297 patients, 21.5% experienced extubation failure. Log Conclusion: Hs-TnT, NT-proBNP and PCT measured on the days before extubation are consistently higher in patients with extubation failure. However, there was no relation between the change in biomarker levels over time and extubation outcome. The serial assessment of Hs-TnT, NT-proBNP, PCT, and IL-6 do not seem to add prognostic information to predict extubation failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.